Small B-cell lymphoma

K34. Kurtin, R J., Hobday, K. S., Ziesmer, S., and Caron, B. L., Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am. J. Clin. Pathol. 112, 319-329 (1999). 

Swerdlow, S. H., Small B-cell lymphomas of the lymph nodes and spleen Practical insights to diagnosis and pathogenesis. Mod. Pathol. 12, 125—140 (1999). 

Watson P, Wood KM, Lodge A, et al. Monoclonal antibodies recognizing CD5, CDIO and CD23 in formalin-fixed, paraffin-embedded tissue production and assessment of their value in the diagnosis of small B-cell lymphoma. Histopathology. 2000 36(2) 145-150. 

Kress, C.L., Konopleva, M., Martinez-Garcia, V., Krajewska, M., Lefebvre, S., Hyer, M.L., McQueen, T., Andreeff., M, Reed, J.C., and Ztqtata, J.M. (2(X)7). Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS ONE 2, e559. 

B cell neoplasms based on morphology, immunophenotype, and genotype often, but not always, correspond to stages of B cell development. However, some B cell lymphomas either do not clearly correspond to a specific developmental stage (i.e., appear to be of variable origin such as chronic lymphocytic leukemia/small lymphocytic lymphoma) or do not appear to be related to any known stage of normal development (i.e., hairy cell leukemia) (H10). 

Scoazec, J. Y., Berger, F., Magaud, J. P., Brochier, J., Coiffier, B., and Bryon, P. A., The dendritic reticulum cell pattern in B cell lymphomas of the small cleaved, mixed, and large cell types An immunohistochemical study of 48 cases. Hum. Pathol. 20, 124—131 (1989). 

An 80-year-old woman with a small B cell extranodal lymphoma was initially given chlorambucil for 10 months, with complete remission for 2 years. When she developed recurrent lymph node sweUing she was given ibritumomab tiuxetan, with near-complete remission. When she developed progressive disease 14 months later, she received cyclophosphamide, vincristine, and prednisone for one cycle. She had persistent pancytopenia, and a bone marrow biopsy showed extensive infiltration by acnte myelogenons lenkemia. 

Monoclonal antibodies to mutated p53 proteins have been developed. The wild type of p53 is normally present in very small amounts that are not detected by immunohisto-chemistry, whereas the mutant protein accumulates to easily detectable levels. Overexpression of the mutant proteins has been detected in up to 70% of primary colorectal cancers. Overexpression of p53 in breast cancers is associated with poor prognosis, but this association is not as strong as the association with c-erhB-2. Up to 75% of small cell lung carcinomas appear to overexpress a mutant (missense mutation) protein. Finally, circulating antibodies to mutant p53 proteins have been found in sera from patients with breast and lung cancer and B-cell lymphomas. Tills antibody response may be useful in this subset of patients for monitoring for relapse. ... 

Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphoblastic leukemia results of cancer and leukemia group B study 9251. J Clin Oncol 2001 19 4014-4022. 

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. 

PURPOSE Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are incurable with standard therapy. 

CD25 functions as a low-affinity interleukin-2 receptor and may be found on a number of cell types including activated T cells. This antigen is characteristically expressed on hairy cell leukemia, mast cell lesions, and certain T-cell malignancies but may be seen at low levels in certain B-cell lymphomas, particularly small cell lymphocytic lymphoma/chronic lymphocytic leukemia. Targeted therapy is available for this antigen (Ontak). 

The majority of these lymphomas demonstrate clonal immunoglobulin gene rearrangements. The most common cytogenetic abnormality identified in this lymphoma is deletions in the long arm of chromosome 6 (del(6)(q21)) with a small number of these lymphomas demonstrating t(9 14)(pl3 32). These translocations are not specific for lymphoplasmacytic lymphoma and have been demonstrated in other B-cell lymphomas. 

Primary lymphomas of the lung comprise less than 1% of all primary pulmonary neoplasms. Small cell lymphomas comprise about 80 to 90% of all primary pulmonary lymphomas with marginal zone B-cell lymphoma representing over 90% of cases. 

---